Christina Annunziata

Christina M. Annunziata, M.D., Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
Women's Malignancies Branch


Dr. Annunziata left CCR in July 2023.  Dr. Annunziata established mechanisms underlying NF-kappaB molecular signal transduction in ovarian cancer. Her genomic profiling and functional screens identified both downstream targets and upstream regulators of this pathway, defining subgroups of patients whose cancers depend on NF-kappaB, and opening up possibilities for novel therapies to treat ovarian cancer. Her clinical trials emphasized collection of patient samples to better understand both predictive and pharmacodynamic markers of treatment response.

Areas of Expertise

Ovarian Cancer
Clinical Trials
Women’s Cancers
Molecular Signal Transduction
Genomic Profiling

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them. 


Selected Key Publications

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline

Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM.
J Clin Oncol.. [Epub ahead of print], 2020. [ Journal Article ]

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.

Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL.
JAMA Oncol. 5(3): 393-401, 2019. [ Journal Article ]

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.

Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, Kohn EC, Annunziata CM, Lipkowitz S, Trepel JB, Sharma R, Mikkilineni L, Gatti-Mays M, Figg WD, Houston ND, Lee JM.
J Immunother Cancer. 7(1): 197, 2019. [ Journal Article ]

NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem-like Cells.

House CD, Jordan E, Hernandez L, Ozaki M, James JM, Kim M, Kruhlak MJ, Batchelor E, Elloumi F, Cam MC, Annunziata CM.
Cancer Res. 77(24): 6927-40, 2017. [ Journal Article ]